Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02271139
Brief Title: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

First Submitted : October 17, 2014
First Submitted that Met QC Criteria : October 20, 2014
First Posted : October 22, 2014 (Estimate)

Last Update Submitted that Met QC Criteria : March 7, 2017
Last Update Posted : March 9, 2017